Table 2.
Ongoing randomized controlled trials on multimodal treatments for resectable esophagogastric junction cancer.
| ClinicalTrials.gov identifier | Phase | Disease | Siewert type | Location | Status | Estimated completion date | Experimental arm | Control arm |
|---|---|---|---|---|---|---|---|---|
| NCT01962246 | II/III | Resectable gastroesophageal junction cancer | II–III | China | Active | December 2018 | Surgery plus perioperative chemoradiotherapy (capecitabine plus oxaliplatin) | Surgery plus postoperative chemotherapy (capecitabine plus oxaliplatin) |
| NCT01523015 | II/III | Resectable gastroesophageal junction cancer | I–III | Poland | Recruiting | December 2020 | Surgery plus preoperative chemoradiotherapy (5-FU plus oxaliplatin plus docetaxel) for Siewert I and II; surgery plus preoperative chemotherapy (5-FU plus oxaliplatin plus docetaxel) for Siewert III | Surgery alone |
| NCT02193594 | II/III | Resectable upper gastric or gastroesophageal junction cancer | NA | China | Recruiting | May 2020 | Surgery plus perioperative chemoradiotherapy (S-1 plus oxaliplatin) | Surgery plus postoperative chemotherapy (S-1 plus oxaliplatin) |
| NCT03349866 | II | HER2-negative resectable gastroesophageal junction cancer | II–III | China | Recruiting | June 2020 | Surgery plus preoperative chemoradiotherapy (capecitabine plus oxaliplatin) plus apatinib | Surgery plus preoperative chemoradiotherapy (capecitabine plus oxaliplatin) |
| NCT03421288 | II | Resectable gastric or gastroesophageal junction cancer | I–III | Germany | Recruiting | February 2025 | Surgery plus perioperative chemotherapy (5-FU plus leucovorin plus oxaliplatin plus docetaxel) plus atezolizumab | Surgery plus perioperative chemotherapy (5-FU plus leucovorin plus oxaliplatin plus docetaxel) |
| NCT02509286 | III | Resectable esophageal or gastroesophageal junction cancer | NA | Germany | Recruiting | June 2024 | Surgery plus perioperative chemotherapy (5-FU plus leucovorin plus oxaliplatin plus docetaxel) | Surgery plus preoperative chemoradiotherapy (carboplatin plus paclitaxel) |
| NCT02205047 | II | HER2-positive resectable gastric or gastroesophageal junction cancer | I–III | Multiple European countries | Recruiting | September 2024 | Surgery plus perioperative chemotherapy (5-FU/capecitabine plus cisplatin) plus trastuzumab plus pertuzumab; surgery plus perioperative chemotherapy (5-FU/capecitabine plus cisplatin) plus trastuzumab | Surgery plus perioperative chemotherapy (5-FU/capecitabine plus cisplatin) |
| NCT01196390 | III | HER2-positive resectable esophageal or gastroesophageal junction cancer | I–III | USA | Active | April 2019 | Surgery plus preoperative chemoradiotherapy (carboplatin plus paclitaxel) plus perioperative trastuzumab | Surgery plus preoperative chemoradiotherapy (carboplatin plus paclitaxel) |
| NCT01726452 | III | Resectable esophageal or gastroesophageal junction cancer | NA | Denmark, France, Ireland, UK | Recruiting | January 2024 | Surgery plus perioperative chemotherapy (5-FU/capecitabine plus cisplatin plus epirubicin) | Surgery plus preoperative chemoradiotherapy (carboplatin plus paclitaxel) |
| NCT01404156 | II/III | Resectable esophageal or gastroesophageal junction cancer | I–II | Canada | Recruiting | April 2021 | Surgery plus preoperative chemoradiotherapy (carboplatin plus paclitaxel) | Surgery plus perioperative chemotherapy (5-FU plus leucovorin plus oxaliplatin plus docetaxel OR 5-FU/capecitabine plus cisplatin plus epirubicin) |
| NCT03013010 | III | Resectable gastric or gastroesophageal junction cancer | II–III | China | Recruiting | December 2023 | Surgery plus perioperative chemoradiotherapy (S-1 plus oxaliplatin) | Surgery plus perioperative chemotherapy (S-1 plus oxaliplatin) |
| NCT02512380 | III | Resectable gastric or gastroesophageal junction cancer | NA | China | Recruiting | July 2021 | Surgery plus perioperative chemotherapy (S-1 plus oxaliplatin plus docetaxel) | Surgery plus perioperative chemotherapy (S-1 plus oxaliplatin) |
| NCT02581462 | II/III | HER2-positive resectable gastric or gastroesophageal junction cancer | I–III | Germany | Active | March 2021 | Surgery plus perioperative chemotherapy (5-FU plus leucovorin plus oxaliplatin plus docetaxel) plus trastuzumab/pertuzumab | Surgery plus perioperative chemotherapy (5-FU plus leucovorin plus oxaliplatin plus docetaxel) |
The search of ongoing trials was conducted on ClinicalTrials.gov. Only phase II and phase III randomized controlled trials with a status of ‘recruiting’ or ‘active’ were included.